Last reviewed · How we verify
NCT05699135
A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer
trial testing Avelumab first-line maintenance in Urinary Bladder Neoplasms in 150 participants. Terminated before completion.
30 June 2023
Quick facts
| Lead sponsor | Pfizer |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 9 March 2023 |
| Primary completion | 30 June 2023 |
| Estimated completion | 30 June 2023 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Avelumab first-line maintenance — full drug profile →
Conditions studied
- Urinary Bladder Neoplasms — all drugs for Urinary Bladder Neoplasms →
- Bladder Cancer — all drugs for Bladder Cancer →
- Bladder Tumors — all drugs for Bladder Tumors →
- Urothelial Carcinoma — all drugs for Urothelial Carcinoma →
Sponsor
Pfizer — full company profile →
Who can join
18 and older, any sex, with Urinary Bladder Neoplasms or Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to learn about the safety and effects of the study medicine (called avelumab) for the treatment of advanced bladder cancer. This study is including participants who: * Participated in the Canadian avelumab patient support program * Have been diagnosed with advanced bladder cancer * Have been treated with platinum-based chemotherapy without their disease progressing All participants in this study have previously received avelumab first-line maintenance for the treatment of their advanced bladder cancer. Pfizer will examine the experiences of people receiving the study medicine. This will help determine the efficacy and safety of the study medicine for the treatment of bladder cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05699135
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Avelumab first-line maintenance
Trials testing the same drug.
- NCT06820255 — DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer. · Phase 4 · recruiting
Other recruiting trials for Urinary Bladder Neoplasms
Currently open trials in the same condition.
- NCT07222488 — A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) · Phase 1, PHASE2 · recruiting
- NCT06421142 — FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer · NA · active not recruiting
- NCT04369560 — Virtual Histology of the Bladder Wall for Bladder Cancer Staging · EARLY_PHASE1 · recruiting
- NCT06960577 — Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cance · Phase 3 · recruiting
- NCT06833073 — A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) · Phase 2 · recruiting
Other Pfizer trials
Trials by the same sponsor.
- NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
- NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
- NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
- NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
- NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05699135 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pfizer
- Last refreshed: 24 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05699135.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing